New Delhi: Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.
“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing.
The company shares were trading up by 4.34 per cent at Rs. 341.25 on the BSE.
Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at email@example.com Contact no. 011-43720751